New data is pointing towards medical cannabis being a promising treatment in managing diabetes.
The cannabis plant has shown that it has a plethora of medicinal uses. Medical cannabis is being used today in a variety of treatments such as, cancer to help with nausea, post-traumatic stress disorder (PTSD), seizure disorders, and more. This intriguing plant may have found its newest purpose as a tool in diabetes management (1).
Researchers Viola Brugnatelli and Fabio Turco wrote The Handbook Principle of Cannabinology where they investigated the medicinal properties medical cannabis could help patients with managing their diabetes (1,2). Brugnatelli and Turco read several studies which are mentioned throughout their book. One of those studies found that cannabis may alter metabolic processes and appetite-regulating hormones. Cannabis was shown to have an effect on hormones such as ghrelin’s effect on adiponectin, which is a hormone that helps with body weight management and blood sugar regulation (1,2). By helping with body weight and regulating blood sugar, cannabis was discovered to promote a decrease chance of developing diabetes.
With a health condition like diabetes, it can come with additional symptoms or complications such as cardiomyopathy, blindness, and nephropathy. In cardiomyopathy, cannabis, particularly the cannabinoid cannabidiol (CBD) showed promising results in preventing pro-inflammatory cascades which can cause cardiovascular dysfunction. In mouse models, CBD helped to benefit several symptoms of diabetic cardiomyopathy (1,2). In regard to blindness or diabetic retinopathy, CBD was shown again to be a beneficial cannabinoid. Through CBD therapy, the cannabinoid exhibited decreasing vascular hyper-permeability, lowering oxidative stress, and preventing retinal cell death (1,2). For nephropathy, CBD provided positive results in renal issues. The cannabinoid may have displayed a new purpose as a treatment option regarding diabetic kidney problems (1,2).
Cannabis as well as cannabinoids like CBD, are showing promising results in helping treat health condition such as diabetes. These results are still in the beginning stages and more research will need to come out in order to provide more thorough and stronger results (1,2). It is interesting to learn another way of how cannabis can benefit more health conditions.
To learn more please visit: https://cannabiscientia.com/handbook/.
References
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.